A Phase 3 interventional study of Velcade and Melphalan in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 160 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.
Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 7th largest by enrollment, is one of 4 that started in 2014, is one of 24 in phase 3, and was the 6th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Eden Biltibo · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Australia, Belgium and 9 more countries
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
By country, each count listing its studies:
daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 84 · Phase 3 25 · Phase 4 4
First in 2008; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 706 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 132 interventional studies. Of the 55 that completed or were terminated, 28 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 132 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 8th largest by enrollment of the 100 interventional ones that give a count, is one of 7 that started in 2014, is one of 35 in phase 3, and was the 56th registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
19 of the studies testing daratumumab in Multiple Myeloma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06952478Phase 3CelltrionA Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma | 2027-03-08 |
| NCT04009109Alliance Foundation Trials, LLC.Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | 2026-12 |
| NCT06697483Peking University People's HospitalRisk Stratification and MRD-driven Maintenance for MM After ASCT | 2026-12-31 |
| NCT04991103University of Alabama at BirminghamMinimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) | 2027-01-01 |
| NCT03829371University of Turin, ItalySTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | 2027-01-03 |
Add all 19 to your calendar (.ics) → With an account.
Among the 132 studies testing daratumumab in Multiple Myeloma, from their registry updates:
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if the addition of daratumumab to velcade (bortezomib) melphalan-prednisone (VMP) will prolong progression-free survival (PFS) compared with VMP alone in participants with previously untreated multiple myeloma who are ineligible for high dose chemotherapy and autologous stem cell transplant (ASCT).
The study consists of 3 phases: Screening Phase (within 21 days prior to randomization), Treatment Phase (Cycle 1 Day 1 to discontinuation of all study treatment), and Follow-up Phase (from discontinuation of all study treatment up to death, lost to follow up, withdrawal of consent, or the study ends, whichever occurs first). Treatment phase will include 2 treatments (Treatment A: participants will receive Velcade MelphalanPrednisone (VMP) alone and Treatment B: participants will receive daratumumab in combination with VMP).Two interim analyses are planned. The first will be to evaluate safety after a total of approximately 100 participants have been treated for at least 2 cycles or discontinued the study treatment. The second will be to evaluate cumulative interim safety and efficacy data, and will be performed when approximately 216 PFS events have been accumulated. The final OS analysis will occur when approximately 382 deaths have occurred. Efficacy will be primarily measured by comparison of PFS between the two treatment arms. Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive velcade (bortezomib) 1.3 milligram per square meter (mg/m\^2) as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m\^2 , orally, once daily (on Days 1-4) and prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
Drug: Velcade · Drug: Melphalan · Drug: Prednisone
Participants will receive velcade 1.3 mg/m\^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m\^2, orally, once daily (on Days 1-4) and prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 mg/kg as IV infusion, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. On days when daratumumab is given, dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute, and prednisone 60 mg/m2 once daily will be given on Days 2-4. Following amendment 7, participants will have the option to switch to daratumumab subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.
Drug: Velcade · Drug: Melphalan · Drug: Prednisone · Drug: Daratumumab IV · Drug: Dexamethasone · Drug: Daratumumab SC
Participants will receive velcade 1.3 mg/m\^2, as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9.
Participants will receive melphalan 9 mg/m\^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
Participants will receive daratumumab 16 mg/kg as intravenous infusion, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study .
Participants administered with dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute.
Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. Following amendment 7, participants can switch from daratumumab IV to daratumumab SC.
Progression Free Survival (PFS)
PFS: duration from date of randomization to progressive disease (PD)/death, whichever occurs first. PD per IMWG criteria-Increase of 25% from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 grams per deciliter \[g/dL\]); Urine M-component (absolute increase \>=200 milligrams \[mg\]/24 hours); Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved free light chain (FLC) levels (absolute increase \>10 mg/dL); Only participants without measurable serum and urine M-protein levels, without measurable disease by FLC levels, bone marrow Plasma cells (PC) percentage (%) (absolute % \>=10%); Bone marrow PC%: absolute% \>10%; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.
Time frame: From randomization (Day -3) up to 2.4 years
Overall Response Rate (ORR)
The Overall response rate was defined as the percentage of participants who achieved a partial response (PR) or better, according to the International Myeloma Working Group (IMWG) criteria, during the study or during follow up. IMWG criteria for PR: greater than or equal to (\>=) 50 percentage (%) reduction of serum M-protein and reduction in 24 hour urinary M-protein by \>=90% or to \<200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow plasma cells (PCs) is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%, in addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas was also required.
Time frame: From randomization (Day -3) up to 2.4 years
Percentage of Participants With Very Good Partial Response (VGPR) or Better
VGPR or better rate was defined as the percentage of participants who achieved VGPR or complete response (CR) (including stringent complete response\[sCR\]) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level less than (\<) 100 milligram (mg) per 24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \< 5% plasms cells (PCs) in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry.
Time frame: From randomization (Day -3) up to 2.4 years
Percentage of Participants With Complete Response (CR) or Better
CR or better rate was defined as the percentage of participants with a CR or better (i.e. CR and sCR) as per IMWG criteria. CR: as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (\<) 5 percent plasma cells in bone marrow; sCR: CR plus normal free light chain (FLC) ratio and absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry.
Time frame: From randomization (Day -3) up to 2.4 years
Percentage of Participants With Stringent Complete Response (sCR)
sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry. CR: Negative immunofixation on the serum and urine; Disappearance of any soft tissue plasmacytomas; \<5% plasma cells (PCs) in bone marrow.
Time frame: From randomization (Day -3) up to 2.4 years
Percentage of Participants With Negative Minimal Residual Disease (MRD)
The Minimal Residual Disease negativity rate was defined as the percentage of participants who had negative MRD (detection of less than 1 malignant cell among 100,000 normal cells) assessment at any timepoint after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood at 10\^-5 threshold. MRD was evaluated by using Deoxyribonucleic acid (DNA) sequencing of immunoglobulin genes. MRD was assessed in participants who achieved complete response or stringent complete response (CR/sCR).
Time frame: From randomization (Day -3) up to 8.3 years
Overall Survival (OS)
Overall Survival (OS) was measured from the date of randomization to date of death. Median Overall Survival was estimated by using the Kaplan-Meier method.
Time frame: From randomization (Day -3) up to 8.3 years
Progression Free Survival on Next Line of Therapy (PFS2)
Progression-free survival after next-line therapy is defined as the time from randomization to progression on the next line of subsequent antimyeloma therapy or death due to any cause (prior to start of second line of antimyeloma therapy), whichever comes first. Disease progression on next line of treatment was based on investigator judgment.
Time frame: From randomization (Day -3) up to 8.3 years
Time to Disease Progression (TTP)
TTP: Time from date of randomization to date of first documented evidence of PD or death due to PD, whichever occurs first. PD per IMWG criteria- Increase of 25 % from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 g/dL); Urine M-component (absolute increase \>=200 mg/24 hours); Only in participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10 milligram per deciliter \[mg/dL\]); Only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cells (PC)% (absolute % \>=10%); Bone marrow PC %: absolute % \>10%; Definite development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.
Time frame: From randomization (Day -3) up to 2.4 years
Time to Response
Time to response, defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for PR or better. PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 hours; If the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria; If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow PCs is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas was also required.
Time frame: From randomization (Day -3) up to 2.4 years
Duration of Response (DOR)
DOR: participants with confirmed response (PR or better) as time between first documentation of response and disease progression per IMWG response criteria, or death due to PD, whichever occurs first. PD: Increase of 25% from lowest response value in any one of following: Serum M-component (absolute increase\>=0.5 g/dL); Urine M-component (absolute increase\>=200 mg/24 hours); Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10mg/dL); Only participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow PC%(absolute%\>=10%); Bone marrow PC's %: absolute%\>10%; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in the size of existing bone lesions or soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.
Time frame: From first documentation of response up to 2.4 years
Time to Next Treatment (TNT)
Time to next treatment is defined as the time from randomization to the start of the next-line treatment. Kaplan-Meier method was used for the analysis.
Time frame: From randomization (Day -3) up to 8.3 years
Percentage of Participants With Best M-protein Response
Percentage of participants with Best M- protein response of 100% reduction and \>=90% to \< 100% reduction were assessed. Best M-protein response was defined as the maximal percent reduction or the lowest percent increase from baseline in serum M-protein for participants with measurable heavy chain at baseline or urine M-protein for participants without measurable heavy chain, but with measurable light chain disease at baseline. For participants without measurable heavy chain and light chain disease at baseline, best response in serum free light chain (FLC) was defined as the maximal percent reduction or the lowest percent increase from baseline in the difference between involved and uninvolved serum FLC level (dFLC).
Time frame: Up to 2.4 years
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30: Emotional Functioning Score
The EORTC QLQ-C30 is a 30 items self-reporting questionnaire, with a 1 week recall period, resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores are transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms. Negative change from baseline values for function and GHS scale indicated deterioration in quality of life or functioning and positive values indicate improvement.
Time frame: Baseline (Day -24), Months 3, 6, 9, 12 ,18, 24, 30, 36, 42 and 48
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30: Global Health Scale
The EORTC QLQ-C30 is a 30 items self-reporting questionnaire, with a 1 week recall period, resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores are transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms. Negative change from baseline values for function and GHS scale indicated deterioration in quality of life or functioning and positive values indicate improvement.
Time frame: Baseline (Day -24), Months 3, 6, 9, 12 ,18, 24, 30, 36, 42 and 48
Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L): Visual Analogue Scale (VAS)
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.
Time frame: Baseline (Day- 24), Months 3, 6, 9, 12 ,18, 24, 30, 36, 42 and 48
Change From Baseline in EuroQol 5 Dimensions-5 Level (EQ-5D-5L) Utility Score
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The EQ-5D-5L descriptive system provides a profile of the participant's health state 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. Responses to the 5 dimension scores were combined and converted into a single preference-weighted health utility index score 0 (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of the individual based on the UK scoring algorithm.
Time frame: Baseline (Day -24), Months 3, 6, 9, 12 ,18, 24, 30, 36, 42 and 48
| Milestone | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Started | 356 | 350 |
| Treated | 354 | 346 |
| Completed | 0 | 0 |
| Not completed | 356 | 350 |
| Withdrew: Lost to follow-up | 18 | 15 |
| Withdrew: Death | 217 | 171 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 30 | 30 |
| Withdrew: Other | 3 | 4 |
| Withdrew: Discontinued at clinical cutoff (due to end of data collection period) | 87 | 130 |
PFS: duration from date of randomization to progressive disease (PD)/death, whichever occurs first. PD per IMWG criteria-Increase of 25% from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 grams per deciliter \[g/dL\]); Urine M-component (absolute increase \>=200 milligrams \[mg\]/24 hours); Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved free light chain (FLC) levels (absolute increase \>10 mg/dL); Only participants without measurable serum and urine M-protein levels, without measurable disease by FLC levels, bone marrow Plasma cells (PC) percentage (%) (absolute % \>=10%); Bone marrow PC%: absolute% \>10%; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.
| Months | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Progression Free Survival (PFS) | 18.14 (16.53 to 19.91) | NA (NA to NA) |
The Overall response rate was defined as the percentage of participants who achieved a partial response (PR) or better, according to the International Myeloma Working Group (IMWG) criteria, during the study or during follow up. IMWG criteria for PR: greater than or equal to (\>=) 50 percentage (%) reduction of serum M-protein and reduction in 24 hour urinary M-protein by \>=90% or to \<200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow plasma cells (PCs) is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%, in addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas was also required.
| Percentage of participants | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Overall Response Rate (ORR) | 73.9 | 90.9 |
VGPR or better rate was defined as the percentage of participants who achieved VGPR or complete response (CR) (including stringent complete response\[sCR\]) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level less than (\<) 100 milligram (mg) per 24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \< 5% plasms cells (PCs) in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry.
| Percentage of participants | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Percentage of Participants With Very Good Partial Response (VGPR) or Better | 49.7 | 71.1 |
CR or better rate was defined as the percentage of participants with a CR or better (i.e. CR and sCR) as per IMWG criteria. CR: as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (\<) 5 percent plasma cells in bone marrow; sCR: CR plus normal free light chain (FLC) ratio and absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry.
| Percentage of participants | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Percentage of Participants With Complete Response (CR) or Better | 24.4 | 42.6 |
sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry. CR: Negative immunofixation on the serum and urine; Disappearance of any soft tissue plasmacytomas; \<5% plasma cells (PCs) in bone marrow.
| Percentage of participants | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Percentage of Participants With Stringent Complete Response (sCR) | 7.0 | 18.0 |
The Minimal Residual Disease negativity rate was defined as the percentage of participants who had negative MRD (detection of less than 1 malignant cell among 100,000 normal cells) assessment at any timepoint after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood at 10\^-5 threshold. MRD was evaluated by using Deoxyribonucleic acid (DNA) sequencing of immunoglobulin genes. MRD was assessed in participants who achieved complete response or stringent complete response (CR/sCR).
| Percentage of participants | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Percentage of Participants With Negative Minimal Residual Disease (MRD) | 7.0 (4.6 to 10.2) | 28.3 (23.6 to 33.3) |
Overall Survival (OS) was measured from the date of randomization to date of death. Median Overall Survival was estimated by using the Kaplan-Meier method.
| Months | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Overall Survival (OS) | 53.59 (46.32 to 60.91) | 82.96 (72.48 to NA) |
Progression-free survival after next-line therapy is defined as the time from randomization to progression on the next line of subsequent antimyeloma therapy or death due to any cause (prior to start of second line of antimyeloma therapy), whichever comes first. Disease progression on next line of treatment was based on investigator judgment.
| Months | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Progression Free Survival on Next Line of Therapy (PFS2) | 42.41 (37.29 to 47.05) | 66.73 (58.58 to 80.07) |
TTP: Time from date of randomization to date of first documented evidence of PD or death due to PD, whichever occurs first. PD per IMWG criteria- Increase of 25 % from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 g/dL); Urine M-component (absolute increase \>=200 mg/24 hours); Only in participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10 milligram per deciliter \[mg/dL\]); Only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cells (PC)% (absolute % \>=10%); Bone marrow PC %: absolute % \>10%; Definite development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.
| Months | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Time to Disease Progression (TTP) | 19.35 (17.38 to 22.67) | NA (NA to NA) |
Time to response, defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for PR or better. PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 hours; If the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria; If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow PCs is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas was also required.
| Months | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Time to Response | 0.82 (0.7 to 12.6) | 0.79 (0.4 to 15.5) |
DOR: participants with confirmed response (PR or better) as time between first documentation of response and disease progression per IMWG response criteria, or death due to PD, whichever occurs first. PD: Increase of 25% from lowest response value in any one of following: Serum M-component (absolute increase\>=0.5 g/dL); Urine M-component (absolute increase\>=200 mg/24 hours); Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10mg/dL); Only participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow PC%(absolute%\>=10%); Bone marrow PC's %: absolute%\>10%; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in the size of existing bone lesions or soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.
| Months | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Duration of Response (DOR) | 21.3 (18.4 to NA) | NA (NA to NA) |
Time to next treatment is defined as the time from randomization to the start of the next-line treatment. Kaplan-Meier method was used for the analysis.
| Months | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Time to Next Treatment (TNT) | 25.9 (23.4 to 28.6) | 66.8 (47.9 to NA) |
Percentage of participants with Best M- protein response of 100% reduction and \>=90% to \< 100% reduction were assessed. Best M-protein response was defined as the maximal percent reduction or the lowest percent increase from baseline in serum M-protein for participants with measurable heavy chain at baseline or urine M-protein for participants without measurable heavy chain, but with measurable light chain disease at baseline. For participants without measurable heavy chain and light chain disease at baseline, best response in serum free light chain (FLC) was defined as the maximal percent reduction or the lowest percent increase from baseline in the difference between involved and uninvolved serum FLC level (dFLC).
| Percentage of participants | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Best M-protein response in serum: 100% reduction | 38.7 | 58.5 |
| Best M-protein response in serum:>= 90 to < 100% | 14.6 | 15.2 |
| Best M-protein response in urine:100% reduction | 69.4 | 90.5 |
| Best M-protein response in urine:>=90 to < 100% | 13.9 | 7.1 |
| Best response in dFLC:100% reduction | 0 | 0 |
| Best response in dFLC: >=90% to < 100% reduction | 77.8 | 100.0 |
The EORTC QLQ-C30 is a 30 items self-reporting questionnaire, with a 1 week recall period, resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores are transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms. Negative change from baseline values for function and GHS scale indicated deterioration in quality of life or functioning and positive values indicate improvement.
| Units on a scale | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Month 3 | 9.4 (7.1 to 11.6) | 8.5 (6.3 to 10.7) |
| Month 6 | 10.5 (8.1 to 12.9) | 10.8 (8.6 to 13.1) |
| Month 9 | 11.8 (9.4 to 14.3) | 11.1 (8.8 to 13.4) |
| Month 12 | 11.2 (8.7 to 13.7) | 12.6 (10.3 to 14.9) |
| Month 18 | 12.8 (10.1 to 15.6) | 12.5 (10.1 to 14.9) |
| Month 24 | 11.8 (8.5 to 15.1) | 10.7 (8.2 to 13.3) |
| Month 30 | 10.8 (7.3 to 14.3) | 12.4 (9.8 to 14.9) |
| Month 36 | 10.8 (6.7 to 14.9) | 12.3 (9.6 to 14.9) |
| Month 42 | 6.5 (1.7 to 11.4) | 12.8 (10 to 15.6) |
| Month 48 | 6.2 (0.5 to 11.9) | 10.5 (7.5 to 13.5) |
The EORTC QLQ-C30 is a 30 items self-reporting questionnaire, with a 1 week recall period, resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores are transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms. Negative change from baseline values for function and GHS scale indicated deterioration in quality of life or functioning and positive values indicate improvement.
| Units on a scale | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Month 3 | 4 (1.7 to 6.3) | 7.5 (5.2 to 9.7) |
| Month 6 | 8.8 (6.4 to 11.3) | 8.5 (6.2 to 10.8) |
| Month 9 | 10.2 (7.7 to 12.8) | 10.6 (8.2 to 12.9) |
| Month 12 | 10.7 (8.2 to 13.3) | 11.4 (9 to 13.7) |
| Month 18 | 11.8 (9 to 14.6) | 12.8 (10.3 to 15.3) |
| Month 24 | 11.5 (8.1 to 15) | 9.5 (6.8 to 12.1) |
| Month 30 | 10.8 (7.1 to 14.5) | 11.8 (9.2 to 14.5) |
| Month 36 | 8.6 (4.2 to 12.9) | 11.9 (9.1 to 14.6) |
| Month 42 | 4.8 (-0.3 to 9.9) | 10.4 (7.5 to 13.3) |
| Month 48 | 8.9 (2.8 to 14.9) | 9.8 (6.6 to 12.9) |
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.
| Units on a scale | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Month 3 | 4.27 ± 18.38 | 9.37 ± 20.222 |
| Month 6 | 7.51 ± 17.957 | 11.02 ± 20.168 |
| Month 9 | 10.08 ± 19.475 | 12.51 ± 20.564 |
| Month 12 | 11.1 ± 19.139 | 10.93 ± 20.447 |
| Month 18 | 10.75 ± 21.146 | 15.35 ± 21.168 |
| Month 24 | 10.62 ± 19.531 | 12.17 ± 22.592 |
| Month 30 | 12.38 ± 21.817 | 14.41 ± 21.305 |
| Month 36 | 12 ± 23.856 | 13.94 ± 21.984 |
| Month 42 | 12.88 ± 23.789 | 14.33 ± 21.502 |
| Month 48 | 9.17 ± 18.612 | 11.93 ± 24.031 |
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The EQ-5D-5L descriptive system provides a profile of the participant's health state 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. Responses to the 5 dimension scores were combined and converted into a single preference-weighted health utility index score 0 (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of the individual based on the UK scoring algorithm.
| Units on a scale | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Month 3 | 0.09 ± 0.312 | 0.12 ± 0.266 |
| Month 6 | 0.12 ± 0.269 | 0.14 ± 0.271 |
| Month 9 | 0.16 ± 0.27 | 0.16 ± 0.271 |
| Month 12 | 0.15 ± 0.281 | 0.17 ± 0.288 |
| Month 18 | 0.14 ± 0.268 | 0.17 ± 0.293 |
| Month 24 | 0.15 ± 0.252 | 0.18 ± 0.312 |
| Month 30 | 0.16 ± 0.291 | 0.19 ± 0.303 |
| Month 36 | 0.16 ± 0.315 | 0.21 ± 0.306 |
| Month 42 | 0.08 ± 0.303 | 0.2 ± 0.287 |
| Month 48 | 0.07 ± 0.246 | 0.15 ± 0.319 |
PFS: duration from date of randomization to PD/death, whichever occurs first. PD per IMWG criteria-Increase of 25% from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 g/dL); Urine M-component (absolute increase \>=200 mg/24 hours); Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10 mg/dL); Only participants without measurable serum and urine M-protein levels, without measurable disease by FLC levels, bone marrow PC %(absolute % \>=10%); Bone marrow PC %: absolute % \>10 %; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in size of existing bone lesions/soft tissue plasmacytomas and development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.
| Months | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| Progression Free Survival at Data Cutoff Date of 24 June 2019 | 19.29 (17.97 to 20.40) | 36.40 (32.13 to 45.90) |
Collected over All cause mortality: From randomization (Day -3) up to 8.3 years; Serious and Other AEs: From start of treatment (Day 1) up to 30 days after last dose of study treatment (up to 8.2 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 217/356 (61%) | 117/354 (33.1%) | 331/354 (93.5%) |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 172/350 (49.1%) | 186/346 (53.8%) | 329/346 (95.1%) |
| Event | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| PneumoniaInfections and infestations | 13/354 | 53/346 |
| BronchitisInfections and infestations | 2/354 | 10/346 |
| Lower Respiratory Tract InfectionInfections and infestations | 3/354 | 10/346 |
| AnaemiaBlood and lymphatic system disorders | 9/354 | 8/346 |
| Cardiac FailureCardiac disorders | 8/354 | 2/346 |
| Upper Respiratory Tract InfectionInfections and infestations | 4/354 | 7/346 |
| Back PainMusculoskeletal and connective tissue disorders | 3/354 | 7/346 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/354 | 7/346 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 7/354 | 2/346 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/354 | 6/346 |
| Event | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 189/354 | 172/346 |
| NeutropeniaBlood and lymphatic system disorders | 186/354 | 174/346 |
| AnaemiaBlood and lymphatic system disorders | 129/354 | 110/346 |
| Peripheral Sensory NeuropathyNervous system disorders | 122/354 | 100/346 |
| Upper Respiratory Tract InfectionInfections and infestations | 48/354 | 103/346 |
| DiarrhoeaGastrointestinal disorders | 87/354 | 100/346 |
| PyrexiaGeneral disorders | 70/354 | 87/346 |
| NauseaGastrointestinal disorders | 76/354 | 76/346 |
| BronchitisInfections and infestations | 25/354 | 71/346 |
| CoughRespiratory, thoracic and mediastinal disorders | 27/354 | 70/346 |
| Age, Continuous(Years) | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | Total |
|---|---|---|---|
| Mean | 71.5 ± 5.82 | 71.3 ± 6.66 | 71.4 ± 6.25 |
| Sex: Female, Male(Participants) | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | Total |
|---|---|---|---|
| Female | 189 | 190 | 379 |
| Male | 167 | 160 | 327 |
| Ethnicity (NIH/OMB)(Participants) | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | Total |
|---|---|---|---|
| Hispanic or Latino | 16 | 24 | 40 |
| Not Hispanic or Latino | 332 | 320 | 652 |
| Unknown or Not Reported | 8 | 6 | 14 |
| Race (NIH/OMB)(Participants) | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 45 | 47 | 92 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 3 | 6 |
| White | 304 | 297 | 601 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 3 | 7 |
| Region of Enrollment(Participants) | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | Total |
|---|---|---|---|
| Argentina | 2 | 2 | 4 |
| Australia | 10 | 5 | 15 |
| Belgium | 8 | 6 | 14 |
| Brazil | 2 | 4 | 6 |
| Bulgaria | 15 | 8 | 23 |
| Croatia | 2 | 2 | 4 |
| Czech Republic | 29 | 21 | 50 |
| Georgia | 11 | 11 | 22 |
| Germany | 2 | 5 | 7 |
| Greece | 15 | 14 | 29 |
| Hungary | 12 | 14 | 26 |
| Italy | 26 | 28 | 54 |
| Japan | 26 | 24 | 50 |
| Poland | 27 | 39 | 66 |
| Portugal | 4 | 3 | 7 |
| Macedonia | 10 | 1 | 11 |
| Romania | 18 | 10 | 28 |
| Russia | 21 | 22 | 43 |
| Serbia | 3 | 7 | 10 |
| Korea, Republic of | 18 | 23 | 41 |
| Spain | 47 | 56 | 103 |
| Turkey | 10 | 5 | 15 |
| Ukraine | 20 | 28 | 48 |
| United Kingdom | 15 | 9 | 24 |
| United States | 3 | 3 | 6 |
| Stage of Disease (ISS)(Participants) | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | Total |
|---|---|---|---|
| Stage I | 67 | 69 | 136 |
| Stage II | 160 | 139 | 299 |
| Stage III | 129 | 142 | 271 |
| Time from multiple myeloma (MM) diagnosis(Months) | Velcade, Melphalan and Prednisone (VMP) | Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | Total |
|---|---|---|---|
| Mean | 1.27 ± 1.737 | 1.09 ± 1.056 | 1.18 ± 1.442 |
Showing the first 100 of 160 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2014 to primary completion in Nov 2017, 35 months.
Results were first posted in Dec 2018, 1 year after primary completion.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 35 months is below that.
Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daratumumab
Janssen Research & Development, LLC →